OBSIDIAN THERAPEUTICS
Dead / Abandoned — Abandoned — no statement of use filed (as of 25 Aug 2025)
What this means for you
This application is over — abandoned 25 Aug 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97765729
- Mark type
- Design + words
- Filed
- 24 Jan 2023
- Published for opposition
- 28 Nov 2023
- Abandoned
- 25 Aug 2025
- Attorney of record
- Olivia Maria Baratta
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations in the fields of cell therapy, gene therapy, oncology, immunotherapy, regenerative medicine, infectious disease, and the prevention and treatment of cardiovascular system disorders, genitourinary system disorders, immune system disorders, metabolic system disorders, musculoskeletal system disorders, nervous system disorders, respiratory system disorders, inflammatory disorders, dermatological disorders and gastroenterological disorders
Owner
- Obsidian Therapeutics, Inc., Cambridge, MA, US
- Obsidian Therapeutics, Inc., Cambridge, MA, US
Prior registrations
Prosecution history
- 25 Aug 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 25 Aug 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Dec 2024 — SOU EXTENSION 2 GRANTED
- 05 Dec 2024 — SOU EXTENSION 2 FILED
- 05 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 27 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Jun 2024 — SOU EXTENSION 1 GRANTED
- 27 Jun 2024 — SOU EXTENSION 1 FILED
- 27 Jun 2024 — SOU TEAS EXTENSION RECEIVED
- 23 Jan 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 Nov 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Nov 2023 — PUBLISHED FOR OPPOSITION
- 08 Nov 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Oct 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER